- Molecular NameEstramustine
- SynonymEstramustin Sodium Phosphate; Estramustina [INN-Spanish]; Estramustine Sodium Phosphate; Estramustinum [INN-Latin]
- Weight440.411
- Drugbank_IDDB01196
- ACS_NO2998-57-4
- Show 2D model
- LogP (experiment)4.636
- LogP (predicted, AB/LogP v2.0)4.37
- pkaN/A
- LogD (pH=7, predicted)4.37
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-6.47
- LogSw (predicted, AB/LogsW2.0)0.04
- Sw (mg/ml) (predicted, ACD/Labs)0.0
- No.of HBond Donors1
- No.of HBond Acceptors4
- No.of Rotatable Bonds6
- TPSA49.77
- StatusFDA approved
- AdministrationN/A
- PharmacologyA chemotherapy agent used to treat prostate cancer.
- Absorption_value75.0
- Absorption (description)Estramustine phosphate taken orally is readily dephosphorylated during absorption, and the major metabolites in plasma are estramustine, the estrone analog, estradiol, and estrone.
- Caco_2N/A
- BioavailabilityN/A
- Protein bindingN/A
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmEMP is a prodrug that is converted to two alkylating metabolites estramustine (EaM) and estromustine (EoM). EaM and EoM are further metabolized to estradiol (E2) and estrone (E1), respectively, via hydrolysis of the carbamate bond.
- Half life20 h
- ExcretionN/A
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityIn a randomized, double-blind trial in 93 patients the following adverse effects were reported with frequency more than 10%: cardiovascular/respiratory: edema, dyspnea; gastrointestinal: nausea, diarrhea, minor gastrointestinal upset; breast changes: tenderness, breast enlargement; elevated levels of lactate dehydrogenase and aspartate aminotransferase in serum.
- LD50 (rat)N/A
- LD50 (mouse)N/A